<em>In vivo</em> synergism of free miltefosine or in alginate-based nanocarrier combined with voriconazole on aspergillosis

Future Microbiol. 2021 Oct 7. doi: 10.2217/fmb-2021-0056. Online ahead of print.


Aim: To evaluate the activity of miltefosine (MFS), in its free form or loaded-alginate nanoparticles (MFS-AN), alone or combined with voriconazole (VRC) on Aspergillus fumigatus and Aspergillus flavus. Materials & methods: Broth microdilution assay was used for susceptibility testing of Aspergillus isolates, and the antifungal efficacy was assessed using the aspergillosis model in Galleria mellonella larvae. Results: The in vitro synergistic effect of MFS with VRC was observed only against A. fumigatus, whereas both combined therapies (MFS + VRC and MFS-AN + VRC) showed synergism in reducing the larval mortality rate and fungal burden in the larvae infected by A. fumigatus and A. flavus. Conclusions: MFS and MFS-AN combined with VRC may be an important strategy for improving antifungal therapy against aspergillosis.

PMID:34615383 | DOI:10.2217/fmb-2021-0056

Source: Industry